Archives
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2018-07
-
SM-164: Bivalent Smac Mimetic Workflow for Robust Apoptosis
2026-07-02
SM-164 enables reproducible, TNFα-dependent apoptosis induction in cancer research, with rapid cIAP-1/2 degradation and robust caspase activation. This guide details best practices, troubleshooting, and protocol optimization for advanced workflows using SM-164 as a high-affinity bivalent Smac mimetic.
-
MK-0812 Empowers Precision Monocyte Trafficking Inhibition
2026-07-02
MK-0812 stands out as a robust, selective CCR2 antagonist for dissecting monocyte recruitment in immune-metabolic models like MASH. This guide translates recent gut–liver axis breakthroughs into actionable workflows, protocol optimization, and troubleshooting insights for applied inflammation research.
-
Palbociclib (PD0332991) Isethionate: Precision Tools for Cel
2026-07-01
Explore the advanced utility of Palbociclib (PD0332991) in dissecting G0/G1 cell cycle arrest and apoptosis induction in cancer models. This article uniquely bridges mechanistic understanding and practical assay design, providing new insights for translational breast and renal cell carcinoma research.
-
VE-821 ATR Kinase Inhibitor: Shaping the Future of DNA Repai
2026-07-01
Explore how VE-821, a potent ATR kinase inhibitor, transforms DNA repair pathway research and radiosensitization assays. This article delivers fresh insights into practical protocol optimization, mechanistic advances, and the intersection of DNA damage response and epigenetic regulation.
-
Firefly Luciferase mRNA (ARCA, 5-moUTP): Applied Workflows &
2026-06-30
Firefly Luciferase mRNA (ARCA, 5-moUTP) delivers robust and reproducible bioluminescent signals for gene expression and cell viability assays, with advanced immune evasion and stability. Explore optimized protocols, troubleshooting strategies, and translational insights that set this reporter apart for both in vitro and in vivo applications.
-
Clozapine and ERK1/2 Signaling: Precision Tools for Next-Gen
2026-06-30
Explore how Clozapine, a leading atypical antipsychotic medication, enables advanced mechanistic assays in schizophrenia research by modulating ERK1/2 and EGF receptor signaling. This article uniquely bridges molecular pharmacology with emerging insights from magnetic neuromodulation, offering novel experimental perspectives.
-
T-5224 (C-Fos/AP-1 Inhibitor): Precision Tools for Inflammat
2026-06-29
T-5224 empowers researchers with highly selective inhibition of c-Fos/AP-1, enabling reproducible control over inflammatory gene expression in arthritis and neuroinflammation models. This article delivers actionable workflows, troubleshooting insights, and comparative advantages rooted in recent discoveries on neuroinflammatory mechanisms.
-
DiscoveryProbe Protease Inhibitor Library: Applied Screening
2026-06-29
The DiscoveryProbe™ Protease Inhibitor Library empowers high throughput and high content screening of protease inhibition across oncology, infectious disease, and cell death research. With validated, cell-permeable inhibitors and robust workflow compatibility, APExBIO’s solution sets a new benchmark for reproducibility and experimental agility.
-
DiscoveryProbe Bioactive Compound Library Plus: Precision Pa
2026-06-28
Explore how the DiscoveryProbe Bioactive Compound Library Plus empowers researchers to unravel complex biological pathways using high-content, pathway-centric screening. This article reveals new strategies for leveraging 5072 bioactive compounds in advanced mechanistic dissection and translational assay optimization.
-
Optimizing Cancer Research with LEE011 Succinate: Protocols
2026-06-27
Harness the power of LEE011 succinate, a highly selective CDK inhibitor, to dissect cell cycle regulation and enhance cancer research workflows. This guide translates bench-validated protocols and the latest reference breakthroughs into actionable, troubleshooting-rich strategies for robust cell proliferation assays.
-
Trelagliptin Succinate Enhances PI-3K/AKT Signaling in Adipo
2026-06-26
The referenced study elucidates the molecular mechanism by which trelagliptin succinate, a DPP-4 inhibitor, improves insulin resistance in adipocytes. Through upregulation of the PI-3K/AKT/GLUT4 pathway and modulation of adipokine secretion, this work advances understanding of insulin signaling and offers actionable insights for metabolic disease research.
-
AM251: Optimizing CB1 Receptor Antagonist Workflows in Resea
2026-06-26
AM251 stands out as a nanomolar-selective CB1 receptor antagonist, enabling precise dissection of endocannabinoid signaling in neuropharmacology and metabolic research. This article delivers actionable protocols, troubleshooting strategies, and insights drawn from recent advances in cannabinoid receptor research, underscoring AM251’s utility for both in vitro and in vivo applications.
-
Recombinant Mouse M-CSF: Molecular Mechanisms and Precision
2026-06-25
Explore the molecular mechanisms of Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) and its role in precise macrophage-based assay development. This article uniquely connects cytokine biology, macrophage metabolic reprogramming, and the latest research on fibrotic disease modeling.
-
2-NBDG Glucose Uptake Assay Kit: Precision in Cancer Metabol
2026-06-25
The 2-NBDG Glucose Uptake Assay Kit empowers researchers to quantify cellular glucose uptake with non-radioactive, single-cell fluorescence—critical for dissecting metabolic reprogramming in cancer and diabetes studies. Its high-throughput workflow, integrated specificity controls, and robust sensitivity drive reproducibility and accelerate metabolic research.
-
Tropifexor (LJN452): Driving Precision in FXR Pathway Resear
2026-06-24
Tropifexor (LJN452) from APExBIO enables precise and potent modulation of the FXR signaling pathway, offering unique advantages in metabolic and intestinal barrier research. This article details advanced experimental workflows, integration of triacetin metabolism insights, and troubleshooting strategies for maximizing FXR-targeted assay performance.